tANCHOR

Fast, Flexible, Variant-Ready.

In the race against evolving SARS-CoV-2 variants, rapid and reliable neutralizing antibody testing is critical. Traditional ELISA systems, while effective, rely on complex and time-consuming protein processing steps that hinder adaptability.

Our tANCHOR cell-based RBD neutralization ELISA eliminates the need for protein purification and plate coating. Designed for speed and versatility, this innovative assay enables monitoring of neutralizing antibodies (NAbs) against emerging variants.

Our assay not only correlates strongly with existing commercial tests but also provides a direct and dynamic measure of RBD-ACE2 interactions on the cell surface. This means faster insights into antibody effectiveness—and more informed decisions for vaccine strategy and public health response.

Choose a smarter, swifter path to immunity insights.

SARS-CoV-2 Neutralization ELISA

Reference

Ivanusic D., Maier J., Icli S., Falcone V., Bernauer H., Bannert N. tANCHOR cell-based assay for SARS- CoV-2 neutralizing antibodies fast adaptive to various receptor-binding domains, iScience, 2024 Feb 5;27(3):109123.

Ivanusic D., Madela K., Burghard H., Holland G., Laue M., Bannert N. tANCHOR: a novel mammalian cell surface peptide display system. Biotechniques. 2021 Jan;70(1):21-28.